Our Pricing

Compare Wegovy Prices UK: Private Prescription Route

Published on: June 03, 2026

When you compare Wegovy prices UK private prescription options, transparent upfront pricing makes all the difference. At Cured Pharmacy, Wegovy starts from £79.00 with no hidden fees, free clinical consultation under 3 minutes, and genuine UK-licensed medication delivered discreetly to your door.

Understanding Wegovy Pricing in the UK Private Market

Wegovy (semaglutide 2.4mg) is a prescription-only GLP-1 receptor agonist licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or above, or 27 kg/m² with weight-related comorbidities [1]. The private prescription route offers faster access than NHS pathways, which currently face significant capacity constraints and strict eligibility criteria.

When comparing private prescription costs, it's essential to look beyond the medication price alone. Total treatment cost includes the prescriber consultation fee, dispensing charges, and delivery—areas where pricing transparency varies considerably across UK online pharmacies. At Cured Pharmacy, our £79.00 starting price includes the clinical assessment by a UK-registered prescriber, with no hidden consultation fees added at checkout.

Wegovy is administered as a once-weekly subcutaneous injection, with dosing escalated gradually over 16-20 weeks to minimise gastrointestinal side effects and improve tolerability [2]. This titration schedule means your monthly cost will vary depending on which dose stage you've reached, making upfront price clarity even more important when budgeting for treatment.

How Wegovy Works: The Science Behind Semaglutide

Semaglutide mimics GLP-1 (glucagon-like peptide-1), a naturally occurring hormone that regulates appetite and food intake through multiple pathways in the brain and gut [1]. By activating GLP-1 receptors in the hypothalamus, Wegovy reduces hunger signals and increases feelings of satiety after meals, making it easier to maintain a reduced-calorie diet.

In the landmark STEP 1 clinical trial, adults using Wegovy 2.4mg alongside lifestyle interventions achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% in the placebo group [2]. Approximately 50% of participants lost at least 15% of their baseline body weight, and nearly one-third lost 20% or more—outcomes that positioned semaglutide as one of the most effective pharmacological weight management options available.

Beyond weight loss, trial data showed improvements in cardiometabolic risk markers including waist circumference, blood pressure, HbA1c, and lipid profiles [2]. These secondary benefits are particularly relevant for patients with obesity-related conditions such as type 2 diabetes, hypertension, or dyslipidaemia, though Wegovy requires clinical assessment to ensure suitability for your individual health profile.

Dosing Schedule and Titration

Wegovy treatment begins at 0.25mg weekly for four weeks, then escalates monthly through 0.5mg, 1mg, and 1.7mg doses before reaching the maintenance dose of 2.4mg weekly [1]. This gradual titration protocol significantly reduces the incidence of nausea and vomiting—the most commonly reported side effects during initiation. Your UK prescriber will monitor your progress and adjust the titration pace if you experience persistent tolerability issues.

Wegovy vs Alternative Weight Loss Treatments

Several prescription weight loss medications are now available through UK private pharmacies, each with distinct mechanisms, efficacy profiles, and cost considerations. Understanding these differences helps you make an informed choice when comparing private prescription options.

Saxenda (liraglutide 3mg) is a daily injectable GLP-1 agonist that predates Wegovy and uses a shorter-acting formulation of the same drug class. While effective, clinical trials show lower average weight loss compared to semaglutide—approximately 8% body weight reduction over 56 weeks in the SCALE trial [3]. The daily injection requirement may suit patients who prefer more frequent dosing control, though weekly administration is generally more convenient for long-term adherence.

Mounjaro (tirzepatide) represents the newest class of weight loss injectable—a dual GIP/GLP-1 receptor agonist that activates two incretin pathways simultaneously. Head-to-head trials suggest tirzepatide may produce greater weight loss than semaglutide, with SURPASS-2 showing average reductions up to 22.5% at the highest dose [4]. However, tirzepatide is currently licensed in the UK primarily for type 2 diabetes, with weight management licensing expected following NICE appraisal.

Oral options like Orlistat (Xenical) and Mysimba work through entirely different mechanisms—lipase inhibition and combined bupropion/naltrexone respectively—and generally produce more modest weight loss of 5-10% [5]. These may be appropriate first-line options for patients who prefer not to use injectables, subject to prescriber assessment of your medical history and treatment goals.

Choosing the Right Treatment for Your Circumstances

Your UK prescriber will assess multiple factors when recommending a weight management medication: your BMI and weight-related health conditions, previous treatment responses, needle tolerance, dosing preference, budget considerations, and any contraindications in your medical history. At Cured Pharmacy, our clinical team includes experienced prescribers who specialise in obesity medicine and can guide you through these options during your free online consultation.

What's Included in Your Wegovy Private Prescription Cost

Transparent pricing should break down exactly what you're paying for. At Cured Pharmacy, our £79.00 Wegovy price includes the medication itself, clinical assessment by a UK-registered prescriber (GMC or NMC registered), electronic prescription generation, pharmacy dispensing and accuracy checking by our superintendent pharmacist Tarun Kumar (GPhC 2233073), and fully discreet packaging with tracked delivery.

Some online providers separate the consultation fee from the medication cost, which can create confusion at checkout and make price comparison difficult. We believe in upfront transparency—the price you see on our product page is the total amount you'll pay, with no hidden consultation charges or membership fees added later.

Your clinical assessment takes under 3 minutes to complete online and covers your medical history, current medications, weight management goals, and any contraindications to GLP-1 therapy. If our prescriber determines Wegovy isn't suitable for your circumstances, you won't be charged—we only dispense when treatment is clinically appropriate and safe. This patient-first approach is central to our GPhC registration (9012511) and commitment to responsible online pharmacy practice.

Eligibility Criteria for Private Wegovy Prescriptions

To receive a private Wegovy prescription in the UK, you must meet specific clinical criteria aligned with MHRA licensing and NICE guidance. Generally, you need a BMI of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidaemia, or obstructive sleep apnoea [1].

Wegovy is contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and should be used cautiously in those with history of pancreatitis, severe gastrointestinal disease, or diabetic retinopathy [1]. Your online assessment will screen for these conditions, and our prescribers may request additional information or decline to prescribe if safety concerns are identified.

Pregnancy and breastfeeding are absolute contraindications to Wegovy use, as GLP-1 agonists cross the placental barrier and may appear in breast milk. Women of childbearing potential should use reliable contraception during treatment and discontinue Wegovy at least 2 months before planned conception [1]. These safety considerations are thoroughly reviewed during your clinical consultation to ensure appropriate prescribing.

Monitoring and Follow-Up Requirements

Effective weight management with Wegovy requires ongoing clinical monitoring to assess treatment response, manage side effects, and adjust therapy as needed. After 12-16 weeks of treatment, your prescriber should review your weight loss progress—NICE recommends considering discontinuation if you haven't achieved at least 5% body weight reduction, as continued use is unlikely to produce clinically meaningful benefit [6]. At Cured Pharmacy, we encourage regular follow-up assessments to optimise your treatment outcomes and ensure safe, effective use throughout your weight loss journey.

How to Start Your Wegovy Private Prescription with Cured Pharmacy

Beginning treatment is straightforward. Visit our Wegovy product page and click 'Start Assessment' to complete the online clinical questionnaire. You'll provide information about your weight, height, medical conditions, current medications, and weight management history—all reviewed confidentially by a UK-registered prescriber within hours.

If approved, your prescription is electronically transmitted to our GPhC-registered pharmacy (9012511) where our team dispenses your medication in accordance with UK pharmacy regulations. We source all Wegovy pens directly from UK-licensed wholesalers, guaranteeing genuine product with full cold-chain integrity maintained throughout storage and dispatch.

Your medication arrives in completely discreet packaging with no external markings indicating contents, delivered via tracked courier to your preferred address. Each Wegovy pen includes full patient information leaflet, dosing instructions, and guidance on injection technique and storage requirements. Our pharmacy team remains available on (+44) 116 4646009 if you have questions about administration, side effects, or your treatment plan after receiving your medication.

Ongoing Prescription Refills and Dose Escalation

As you progress through the Wegovy titration schedule, you'll need prescriptions for each new dose strength. Our system makes reordering simple—log into your account when you're ready to escalate to the next dose, complete a brief follow-up assessment, and our prescribers will review your progress before issuing the next prescription. This ensures continuous clinical oversight throughout your treatment journey while maintaining the convenience of online access.

Scientific References

1. Electronic Medicines Compendium. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen - Summary of Product Characteristics. Novo Nordisk Limited. https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
4. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
5. National Institute for Health and Care Excellence. (2014). Obesity: identification, assessment and management (CG189). NICE. https://www.nice.org.uk/guidance/cg189 [accessed 13 August 2026]
6. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity (TA875). NICE. https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Wegovy is a prescription-only medication licensed for chronic weight management in adults with obesity or overweight with weight-related comorbidities. Individual results may vary. Always consult a qualified healthcare professional before starting any new medication or weight loss programme.